|
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
RECRUITINGPhase 1Sponsored by Viking Therapeutics, Inc.
Actively Recruiting
PhasePhase 1
SponsorViking Therapeutics, Inc.
Started2026-07-06
Est. completion2026-10-02
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07846033
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.
Eligibility
Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria: * Must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). * Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator. * Body mass index ≥ 27 kg/m2 and \< 40 kg/m2. * Willing to comply with contraceptive requirements. Exclusion Criteria: * Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history or laboratory testing, as assessed by the Investigator. * Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption. * History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant. * Current or prior diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes). * History of, or current, clinically significant liver disease, gallbladder disease (with the exception of Gilbert's Syndrome), as assessed by the Investigator. * History of drug or alcohol abuse (ie, \>14 drinks/week for women or 21 drinks/week for men \[1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor\]) within 12 months of Screening.
Conditions2
Obese AdultsWeight Loss
Interventions2
Locations1 site
Viking Clinical Site #001
Find trials near these locations
Related trials
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery — Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis — Novartis Pharmaceuticals
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer — BioNTech SE
- Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma — University of Colorado, Denver
- Empagliflozin in Patients With Cirrhosis and Ascites — Yale University
- A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes — Hua Medicine Limited
- Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study — Rajesh Kumar
- Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes — University of Colorado, Denver
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1
SponsorViking Therapeutics, Inc.
Started2026-07-06
Est. completion2026-10-02
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07846033